Phospholipids Trigger
Capsular Enlargement during Interactions with Amoebae and
Macrophages
A remarkable aspect of the interaction of Cryptococcus
neoformans with mammalian hosts is a consistent increase in capsule
volume. Given that many aspects of the interaction of C.
neoformans with macrophages are also observed with amoebae, we
hypothesized that the capsule enlargement phenomenon also had a protozoan
parallel. Incubation of C. neoformans with Acanthamoeba
castellanii resulted in C. neoformans capsular
enlargement. The phenomenon required contact between fungal and protozoan cells
but did not require amoeba viability. Analysis of amoebae extracts showed that
the likely stimuli for capsule enlargement were protozoan polar lipids. Extracts
from macrophages and mammalian serum also triggered cryptococcal capsular
enlargement. C. neoformans capsule enlargement required
expression of fungal phospholipase B, but not phospholipase C. Purified
phospholipids, in particular, phosphatidylcholine, and derived molecules
triggered capsular enlargement with the subsequent formation of giant cells.
These results implicate phospholipids as a trigger for both C.
neoformans capsule enlargement in vivo and
exopolysaccharide production. The observation that the incubation of C.
neoformans with phospholipids led to the formation of giant cells
provides the means to generate these enigmatic cells in vitro.
Protozoan- or mammalian-derived polar lipids could represent a danger signal for
C. neoformans that triggers capsular enlargement as a
non-specific defense mechanism against potential predatory cells. Hence,
phospholipids are the first host-derived molecules identified to trigger
capsular enlargement. The parallels apparent in the capsular response of
C. neoformans to both amoebae and macrophages provide
additional support for the notion that certain aspects of cryptococcal virulence
emerged as a consequence of environmental interactions with other microorganisms
such as protists.
Vyšlo v časopise:
Phospholipids Trigger
Capsular Enlargement during Interactions with Amoebae and
Macrophages. PLoS Pathog 7(5): e32767. doi:10.1371/journal.ppat.1002047
Kategorie:
Research Article
prolekare.web.journal.doi_sk:
https://doi.org/10.1371/journal.ppat.1002047
Souhrn
A remarkable aspect of the interaction of Cryptococcus
neoformans with mammalian hosts is a consistent increase in capsule
volume. Given that many aspects of the interaction of C.
neoformans with macrophages are also observed with amoebae, we
hypothesized that the capsule enlargement phenomenon also had a protozoan
parallel. Incubation of C. neoformans with Acanthamoeba
castellanii resulted in C. neoformans capsular
enlargement. The phenomenon required contact between fungal and protozoan cells
but did not require amoeba viability. Analysis of amoebae extracts showed that
the likely stimuli for capsule enlargement were protozoan polar lipids. Extracts
from macrophages and mammalian serum also triggered cryptococcal capsular
enlargement. C. neoformans capsule enlargement required
expression of fungal phospholipase B, but not phospholipase C. Purified
phospholipids, in particular, phosphatidylcholine, and derived molecules
triggered capsular enlargement with the subsequent formation of giant cells.
These results implicate phospholipids as a trigger for both C.
neoformans capsule enlargement in vivo and
exopolysaccharide production. The observation that the incubation of C.
neoformans with phospholipids led to the formation of giant cells
provides the means to generate these enigmatic cells in vitro.
Protozoan- or mammalian-derived polar lipids could represent a danger signal for
C. neoformans that triggers capsular enlargement as a
non-specific defense mechanism against potential predatory cells. Hence,
phospholipids are the first host-derived molecules identified to trigger
capsular enlargement. The parallels apparent in the capsular response of
C. neoformans to both amoebae and macrophages provide
additional support for the notion that certain aspects of cryptococcal virulence
emerged as a consequence of environmental interactions with other microorganisms
such as protists.
Zdroje
1. MaHMayRC
2009
Virulence in Cryptococcus species.
Adv Appl Microbiol
67
131
190
2. DoeringTL
2009
How sweet it is! Cell wall biogenesis and polysaccharide capsule
formation in Cryptococcus neoformans.
Annu Rev Microbiol
63
223
247
3. ZaragozaORodriguesMLDeJMFrasesSDadachovaE
2009
The capsule of the fungal pathogen Cryptococcus
neoformans.
Adv Appl Microbiol
68
133
216
4. ZaragozaOChrismanCJCastelliMVFrasesSCuenca-EstrellaM
2008
Capsule enlargement in Cryptococcus neoformans
confers resistance to oxidative stress suggesting a mechanism for
intracellular survival.
Cell Microbiol
10
2043
2057
5. AlspaughJAPukkila-WorleyRHarashimaTCavalloLMFunnellD
2002
Adenylyl cyclase functions downstream of the Galpha protein Gpa1
and controls mating and pathogenicity of Cryptococcus
neoformans.
Eukaryot Cell
1
75
84
6. ZaragozaOGarcia-RodasRNosanchukJDCuenca-EstrellaMRodriguez-TudelaJL
2010
Fungal cell gigantism during mammalian infection.
PLoS Pathog
6
e1000945
7. OkagakiLHStrainAKNielsenJNCharlierCBaltesNJ
2010
Cryptococcal cell morphology affects host cell interactions and
pathogenicity.
PLoS Pathog
6
e1000953
8. ZaragozaOFriesBCCasadevallA
2003
Induction of capsule growth in Cryptococcus
neoformans by mammalian serum and CO(2).
Infect Immun
71
6155
6164
9. ZaragozaOTabordaCPCasadevallA
2003
The efficacy of complement-mediated phagocytosis of
Cryptococcus neoformans is dependent on the location of
C3 in the polysaccharide capsule and involves both direct and indirect
C3-mediated interactions.
Eur J Immunol
33
1957
1967
10. FeldmesserMKressYNovikoffPCasadevallA
2000
Cryptococcus neoformans is a facultative
intracellular pathogen in murine pulmonary infection.
Infect Immun
68
4225
4237
11. TuckerSCCasadevallA
2002
Replication of Cryptococcus neoformans in
macrophages is accompanied by phagosomal permeabilization and accumulation
of vesicles containing polysaccharide in the cytoplasm.
Proc Natl Acad Sci
99
3165
3170
12. BuntingLANeilsonJBBulmerGS
1979
Cryptococcus neoformans: gastronomic delight of
a soil ameba.
Sabouraudia
17
225
232
13. SteenbergenJNShumanHACasadevallA
2001
Cryptococcus neoformans interactions with
amoebae suggest an explanation for its virulence and intracellular
pathogenic strategy in macrophages.
Proc Natl Acad Sci
18
15245
15250
14. BidochkaMJClarkDCLewisMWKeyhaniNO
2010
Could insect phagocytic avoidance by entomogenous fungi have
evolved via selection against soil amoeboid predators?
Microbiology
156
2164
2171
15. FragerSZChrismanCJShakkedRCasadevallA
2010
Paramecium species ingest and kill the cells of the human
pathogenic fungus Cryptococcus neoformans.
Med Mycol
48
775
779
16. CasadevallANosanchukJDSteenbergenJN
2003
‘Ready-made’ virulence and ‘dual-use’
virulence factors in pathogenic enviromental fungi - the
Cryptococcus neoformans paradigm.
Curr Opin Microbiol
112
1164
1175
17. SteenbergenJNCasadevallA
2003
The origin and maintenance of virulence for the human pathogenic
fungus Cryptococcus neoformans.
Microbes Infect
5
667
675
18. CasadevallAPirofskiLA
2007
Accidental virulence, cryptic pathogenesis, martians, lost hosts,
and the pathogenicity of environmental microbes.
Eukaryot Cell
6
2169
2174
19. AlvarezMCasadevallA
2006
Phagosome fusion and extrusion, and host cell survival following
Cryptococcus neoformans phagocytosis by
macrophages.
Curr Biol
16
2161
2165
20. MaHCroudaceJELammasDAMayRC
2006
Expulsion of live pathogenic yeast by
macrophages.
Curr Biol
16
2156
2160
21. ChrismanCJAlvarezMCasadevallA
2010
Phagocytosis and non-lytic phagocytosis of Cryptococcus
neoformans by, and from, Acanthamoeba
castellanii.
Appl Environ Microbiol
76
6056
6062
22. ZaragozaOCasadevallA
2004
Experimental modulation of capsule size in Cryptococcus
neoformans.
Biol Proced Online
6
10
15
10.1251/bpo68 [doi]
23. FolchJLeesMSloaneS
1957
A simple method for the isolation and purification of total
lipides from animal tissues.
J Biol Chem
226
497
509
24. CoxGMMcDadeHCChenSCTuckerSCGottfredssonM
2001
Extracellular phospholipase activity is a virulence factor for
Cryptococcus neoformans.
Mol Microbiol
39
166
175
25. NoverrMCErb-DownwardJRHuffnagleGB
2003
Production of eicosanoids and other oxylipins by pathogenic
eukaryotic microbes.
Clin Microbiol Rev
16
517
533
26. ChenSCWrightLCSantangeloRTMullerMMoranVR
1997
Identification of extracellular phospholipase B,
lysophospholipase, and acyltransferase produced by Cryptococcus
neoformans.
Infect Immun
65
405
411
27. GanendrenRWidmerFSinghalVWilsonCSorrellT
2004
In vitro antifungal activities of inhibitors of phospholipases
from the fungal pathogen Cryptococcus
neoformans.
Antimicrob Agents Chemother
48
1561
1569
28. ChenSCWrightLCGoldingJCSorrellTC
2000
Purification and characterization of secretory phospholipase B,
lysophospholipase and lysophospholipase/transacylase from a virulent strain
of the pathogenic fungus Cryptococcus neoformans.
Biochem J
347
431
439
29. GrangerDLPerfectJRDurackDT
1985
Virulence of Cryptococcus neoformans. Regulation
of capsule synthesis by carbon dioxide.
J Clin Invest
76
508
516
30. VartivarianSEAnaissieEJCowartRESpriggHATinglerMJ
1993
Regulation of cryptococcal capsular polysaccharide by
iron.
J Infect Dis
167
186
190
31. FeldmesserMKressYCasadevallA
2001
Dynamic changes in the morphology of Cryptococcus
neoformans during murine pulmonary infection.
Microbiology
147
2355
2365
32. RuizANeilsonJBBulmerGS
1982
Control of Cryptococcus neoformans in nature by
biotic factors.
Sabouraudia
20
21
29
33. ShahidiFWanasundaraPKJDP
2008
Extraction and analysis of lipids.
AkohCCMinDB
Food Lipids: Chemistry, Nutrition and Biotechnology
Boca Raton, Fl
CRC Press
125
156
34. ChristieWW
1993
Preparation of lipid extracts from tissues.
ChristieWW
Advances in Lipid Methodology
Dundee
Oily Press
195
213
35. FrasesSNimrichterLVianaNBNakouziACasadevallA
2008
Cryptococcus neoformans capsular polysaccharide
and exopolysaccharide fractions manifest physical, chemical, and antigenic
differences.
Eukaryot Cell
7
319
327
36. FallbrookATurenneSDMamaliasNKishSJRossBM
1999
Phosphatidylcholine and phosphatidylethanolamine metabolites may
regulate brain phospholipid catabolism via inhibition of lysophospholipase
activity.
Brain Res
834
207
210
S0006-8993(99)01570-X [pii]
37. CharlierCChretienFBaudrimontMMordeletELortholaryO
2005
Capsule structure changes associated with Cryptococcus
neoformans crossing of the blood-brain barrier.
Am J Pathol
166
421
432
38. XuYLiuYRidgwayNDMcMasterCR
2001
Novel members of the human oxysterol-binding protein family bind
phospholipids and regulate vesicle transport.
J Biol Chem
276
18407
18414
39. ImYJRaychaudhuriSPrinzWAHurleyJH
2005
Structural mechanism for sterol sensing and transport by
OSBP-related proteins.
Nature
437
154
158
40. FairnGDMcMasterCR
2005
Identification and assessment of the role of a nominal
phospholipid binding region of ORP1S (oxysterol-binding-protein-related
protein 1 short) in the regulation of vesicular transport.
Biochem J
387
889
896
41. YonedaADoeringTL
2006
A eukaryotic capsular polysaccharide is synthesized
intracellularly and secreted via exocytosis.
Mol Biol Cell
17
5131
5140
42. ChenL-CBlankECasadevallA
1996
Extracellular proteinase activity of Cryptococcus
neoformans.
Clin Diagn Lab Immunol
3
570
574
43. MoffatJFTompkinsLS
1992
A quantitative model of intracellular growth of
Legionella pneumophila in Acanthamoeba
castellanii.
Infect Immun
60
296
301
44. SheaJMKechichianTBLubertoCDel PoetaM
2006
The cryptococcal enzyme inositol
phosphosphingolipid-phospholipase C confers resistance to the antifungal
effects of macrophages and promotes fungal dissemination to the central
nervous system.
Infect Immun
74
5977
5988
45. UlsamerAGSmithFRKornED
1969
Lipids of Acanthamoeba castellanii. Composition
and effects of phagocytosis on incorporation of radioactive
precursors.
J Cell Biol
43
105
114
46. CasadevallAMukherjeeJScharffMD
1992
Monoclonal antibody ELISAs for cryptococcal
polysaccharide.
J Immunol Meth
154
27
35
47. GuimaraesAJAlmeidaMAPizziniCVPeraltaJMNosanchukJD
2010
Evaluation of an enzyme linked immunosorbent assay (ELISA) using
purified, deglycosylated histoplasmin for different clinical manifestations
of histoplasmosis.
Microbiol Res
2
10.4081/mr.2009.e1
48. CasadevallACleareWFeldmesserMGlatman-FreedmanAGoldmanDL
1998
Characterization of a murine monoclonal antibody to
Cryptocococcus neoformans polysaccharide that is a
candidate for human therapeutic studies.
Antimicrob Agents Chemotherap
42
1437
1446
Štítky
Hygiena a epidemiológia Infekčné lekárstvo LaboratóriumČlánok vyšiel v časopise
PLOS Pathogens
2011 Číslo 5
- Parazitičtí červi v terapii Crohnovy choroby a dalších zánětlivých autoimunitních onemocnění
- Očkování proti virové hemoragické horečce Ebola experimentální vakcínou rVSVDG-ZEBOV-GP
- Koronavirus hýbe světem: Víte jak se chránit a jak postupovat v případě podezření?
Najčítanejšie v tomto čísle
- Crystal Structure and Functional Analysis of the SARS-Coronavirus RNA Cap 2′-O-Methyltransferase nsp10/nsp16 Complex
- The OXI1 Kinase Pathway Mediates -Induced Growth Promotion in Arabidopsis
- The Hexamer Structure of the Rift Valley Fever Virus Nucleoprotein Suggests a Mechanism for its Assembly into Ribonucleoprotein Complexes
- Acquisition of Human-Type Receptor Binding Specificity by New H5N1 Influenza Virus Sublineages during Their Emergence in Birds in Egypt